The tweet was deleted by the author.
But we saved everything 🙂.
Eli Lilly announced a $6.5 billion groundbreaking for a new manufacturing facility in Houston, Texas, as part of its $50 billion push to expand U.S. drug production and job creation. Shares edge higher on the day, trading at $1,170.
Eli Lilly announced on September 21, 2026, that it broke ground on a new manufacturing site in Houston, Texas. The facility is part of the companys $50+ billion investment in domestic production and will create hundreds of jobs. The Houston site will manufacture Foundayo (orforglipron), as well as other small-molecule medicines and advanced therapeutics, according to ABC13 Houston.
View post on X Loading...
Price is sitting right at resistance from the weekly high at $1,170. The daily chart shows a split structure, as shares remain below the MA-50 but above the MA-20 and MA-200. Stoch RSI is in overbought territory, which limits room for further upside and contributes to the muted response in price action.
To gauge whether buyers are embracing the recent event, traders should look for a decisive move through resistance at $1,170. Shares are currently testing this level without managing to break above it. The move over the past week has been contained within a narrow range; even so, the probabilities over the coming trading week stand at 75% for upside and 25% for downside, with an expected trading range between $1,153 and $1,187. A close above $1,170 would show buyers are willing to follow through, while a drop below $1,158 would indicate the advance is being faded. On the weekly chart the longer-term picture stays firmly constructive.
Previously it was reported that the FDA approved an additional cardiovascular indication for Eli Lilly's diabetes drug, supporting a constructive long-term technical view despite mixed near-term signals. The recent manufacturing expansion in Houston adds a new dimension to the story, with traders now focusing on whether shares can decisively clear $1,170 resistance to sustain further gains.